Global sales of HIV/AIDS drugs could reach $10.6 billion by 2015, up from $7.1 billion in 2005, according to a report from market researcher Datamonitor. Drug companies may be pressured to cut prices in developing nations, but the West remains a lucrative and fast-growing market. Firms such as Merck, Pfizer, Gilead Sciences and Johnson & Johnson may benefit most from the market growth, the report said.

Full Story:

Related Summaries